Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionVericel Corporation Common Stock (VCEL)
Fair value (4 models)
Not available
ACCE price target
$38.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $42.53 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
63
out of 100
Analysts
88% buy
8 covering
P/E
90.5x
forward 50.3x
1-year return
+18.2%
Dividend yield
0.00%
Vericel Corporation Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Vericel makes cell and tissue therapies, chiefly MACI for cartilage repair in the knee and Epicel and NexoBrid for severe burns, and sells them to hospitals and specialty clinics. The structural appeal is the gross margin of 74.6% on a product that requires surgical procedures and manufacturing capacity few competitors can match quickly. Revenue is growing 22.5%, and the forward P/E of 57.1 against a trailing 87.3 suggests the market is pricing in earnings expansion as the cost base scales. The operating margin of 0.6% shows that scale has not yet reached the bottom line, so the thesis depends on operating leverage arriving. At a 59/100 score and a $2.1B market cap, the name is worth a deeper look mainly to test whether that margin gap closes on schedule.